This morning, AtaiBeckley shared positive topline data from the open-label portion of its Phase 2b trial of intranasal 5-MeO-DMT (BPL-003) in patients with treatment-resistant depression (TRD).
The open-label extension (OLE) saw participants offered a second, 12 mg dose of the short-acting psychedelic after the 8-week blinded period during which they received one of three first doses (0.3 mg, 8 mg, or 12 mg).
AtaiBeckley, which just last week adopted its present name after a merger between atai Life Sciences and Beckley Psytech closed, reports that the second dose “produced additional rapid, clinically meaningful antidepressant effects that were sustained for up to eight weeks”.
We reviewed the readout and spoke with AtaiBeckley CEO, Srinivas Rao, to dive a little deeper…
Sign-in or join Pα+ to continue reading this article…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue
